The DJS Law Group announced an investigation into aTyr Pharma, Inc. for potential violations of securities laws. This investigation follows the company's announcement on September 15, 2025, that its experimental drug, efzofitimod, failed to meet the main goal in a late-stage study for pulmonary sarcoidosis.
Reuters reported on September 15, 2025, that aTyr Pharma's experimental drug did not meet the primary endpoint in its Phase 3 study. This news led to a significant decline in the company's stock.
The investigation focuses on whether aTyr Pharma issued misleading statements or failed to disclose pertinent information to investors prior to the announcement of the Phase 3 trial results.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.